WATERTOWN, Mass.--(BUSINESS WIRE)--March 7, 2006--Acusphere, Inc. (NASDAQ: ACUS) today announced that it has completed enrollment in its “32" trial, one of two Phase 3 clinical trials for the Company’s lead product candidate, AI-700. The Company has closed this trial and anticipates making a public announcement about the data from this trial before the end of the second quarter 2006. Based upon estimates and assumptions derived primarily from its previous clinical trials for AI-700, the Company believes that it has enrolled enough patients in both the “32" trial and the “33" trial to be able to achieve statistical significance in both of these trials. The Company believes that continuing to enroll patients in the 33 trial should increase the probability of success of this trial without delaying the NDA filing date. Therefore, the Company also said it plans to continue to enroll patients in its “33" trial through the end of the second quarter and anticipates making a public announcement about the data from this trial during the fourth quarter 2006. Completing the qualification of the Company’s commercial manufacturing facility is currently on the critical path to an NDA filing for AI-700 which is expected during the first half of 2007.
